About the Panel

Clodronate has been approved by the FDA to control the signs of navicular syndrome in horses since 2014.

In the five years since the approval, clodronate—a non-nitrogenous bisphosphonate drug—has changed the way in which equine practitioners manage lameness and other conditions with bone involvement. However, non-judicious use of clodronate and the use of nitrogenous bisphosphonates, a much more potent class that is not approved for horses, has led to confusion and concern among equine practitioners about the efficacy and safety of the drug.

In May of 2019, LifeLearn Animal Health facilitated a panel discussion with leading equine medicine experts who have had extensive experience with clodronate use from both research and clinical viewpoints. In this panel, representatives from academia, English performance, and Western performance discussed their own experience with the judicious use of clodronate for managing lameness and other painful bone conditions.